{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=52", "query": { "condition": "Normal Pregnancy", "page": 52 }, "page_size": 10 }, "pagination": { "page": 52, "page_size": 10, "total_count": 1973, "total_pages": 198, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=53&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Pregnancy&page=51&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T04:34:32.888Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04553133", "title": "PF-07104091 as a Single Agent and in Combination Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Ovarian Cancer", "Breast Cancer" ], "interventions": [ { "name": "PF-07104091 monotherapy dose escalation", "type": "DRUG" }, { "name": "PF-07104091 + palbociclib + fulvestrant", "type": "DRUG" }, { "name": "PF-07104091 + palbociclib + letrozole", "type": "DRUG" }, { "name": "PF-07104091 monotherapy dose expansion (ovarian)", "type": "DRUG" }, { "name": "PF-07104091 monotherapy dose expansion (SCLC)", "type": "DRUG" }, { "name": "PF-07104091 + Fulvestrant (post CDK4/6)", "type": "DRUG" }, { "name": "PF-0704091 + Fulvestrant (post CDK4/6)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 157, "start_date": "2020-09-16", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-11-03T04:34:32.888Z", "location_count": 17, "location_summary": "Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more", "locations": [ { "city": "Clive", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04553133" }, { "nct_id": "NCT01893138", "title": "Autologous Muscle Derived Cells for Female Urinary Sphincter Repair", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stress Urinary Incontinence" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Iltamiocel", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Cook MyoSite", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 311, "start_date": "2013-11-21", "completion_date": "2020-11-10", "has_results": true, "last_update_posted_date": "2023-01-05", "last_synced_at": "2026-11-03T04:34:32.888Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Agoura Hills, California • Los Angeles, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Agoura Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Weston", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01893138" }, { "nct_id": "NCT00248404", "title": "NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "NB1011", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kiadis Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2005-09", "completion_date": "2007-12-12", "has_results": false, "last_update_posted_date": "2022-05-16", "last_synced_at": "2026-11-03T04:34:32.888Z", "location_count": 2, "location_summary": "Los Angeles, California • Minneapolis, Minnesota", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00248404" }, { "nct_id": "NCT04596033", "title": "TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Small-cell Lung Cancer", "Cutaneous Squamous Cell Carcinoma", "Anal Squamous Cell Carcinoma", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "GEN-011", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genocea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2020-11-11", "completion_date": "2022-06-27", "has_results": false, "last_update_posted_date": "2022-07-15", "last_synced_at": "2026-11-03T04:34:32.888Z", "location_count": 8, "location_summary": "Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04596033" }, { "nct_id": "NCT01793584", "title": "Surgical Success After Laparoscopic vs Abdominal Hysterectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metrorrhagia", "Menorrhagia", "Leiomyoma", "Adenomyosis", "Pelvic Pain", "Endometriosis", "Pelvic Inflammatory Disease" ], "interventions": [ { "name": "Laparoscopic hysterectomy", "type": "PROCEDURE" }, { "name": "Abdominal hysterectomy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 100, "start_date": "2013-02", "completion_date": "2016-12-31", "has_results": false, "last_update_posted_date": "2017-10-26", "last_synced_at": "2026-11-03T04:34:32.888Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01793584" }, { "nct_id": "NCT02085538", "title": "Study Of Palbociclib (PD-0332991) In Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Impairment" ], "interventions": [ { "name": "palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 31, "start_date": "2014-05", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2018-04-30", "last_synced_at": "2026-11-03T04:34:32.888Z", "location_count": 3, "location_summary": "DeLand, Florida • Orlando, Florida • Saint Paul, Minnesota", "locations": [ { "city": "DeLand", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02085538" }, { "nct_id": "NCT01546363", "title": "Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Blood draw", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2012-02-24", "completion_date": "2020-06-29", "has_results": false, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-11-03T04:34:32.888Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01546363" }, { "nct_id": "NCT02009449", "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Prostate Cancer", "Ovarian Cancer", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Pancreatic Carcinoma", "Non-small Cell Lung Carcinoma", "Solid Tumors", "Breast Cancer" ], "interventions": [ { "name": "Pegilodecakin", "type": "DRUG" }, { "name": "Paclitaxel or Docetaxel and Carboplatin or Cisplatin", "type": "DRUG" }, { "name": "FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)", "type": "DRUG" }, { "name": "gemcitabine/nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "Gemcitabine/carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 353, "start_date": "2013-11-15", "completion_date": "2023-07-22", "has_results": true, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-11-03T04:34:32.888Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02009449" }, { "nct_id": "NCT02150148", "title": "Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Experimental: Mentored Gardening Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 46, "start_date": "2014-04", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-02-09", "last_synced_at": "2026-11-03T04:34:32.888Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02150148" }, { "nct_id": "NCT01552434", "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Neoplasm", "Castleman Disease", "Digestive System Carcinoma", "Erdheim-Chester Disease", "Lip and Oral Cavity Carcinoma", "Lymphangioleiomyomatosis", "Malignant Endocrine Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Male Reproductive System Neoplasm", "Malignant Neoplasm", "Malignant Respiratory Tract Neoplasm", "Malignant Thoracic Neoplasm", "Malignant Urinary System Neoplasm", "Mesothelial Neoplasm", "Metastatic Malignant Neoplasm", "Metastatic Urothelial Carcinoma", "Neurofibromatosis Type 2", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Breast Carcinoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Digestive System Carcinoma", "Recurrent Female Reproductive System Carcinoma", "Recurrent Male Reproductive System Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Pharyngeal Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Malignant Neoplasm", "Soft Tissue Neoplasm", "Stage III Breast Cancer AJCC v7", "Stage III Pharyngeal Cancer", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Pharyngeal Cancer", "Stage IVA Pharyngeal Cancer", "Stage IVB Pharyngeal Cancer", "Stage IVC Pharyngeal Cancer", "Thyroid Gland Neoplasm" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 154, "start_date": "2012-10-16", "completion_date": "2026-05-08", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-11-03T04:34:32.888Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552434" } ] }